DOI:
10.1055/s-00000004
Aktuelle Neurologie
LinksClose Window
References
Cohen JA, Coles AJ, Arnold DL. et al.
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial.
Lancet 2012;
380: 1819-1828
We do not assume any responsibility for the contents of the web pages of other providers.